Get started

Healthcarestocks

Can a Pharmaceutical Giant Rewrite Its Own Destiny?In the complex world of global pharmaceuticals, Teva Pharmaceutical Industries Ltd. emerges as a compelling narrative of strategic reinvention. Under the leadership of CEO Richard Francis, the company has transformed from a struggling enterprise to a potential market leader, executing a bold "Pivot to Growth" strategy that has captured the attention of investors and industry experts alike. The company's remarkable journey reflects corporate resilience and a profound understanding of how strategic focus and innovative thinking can resurrect a seemingly faltering business. Teva's renaissance is characterized by calculated moves that challenge traditional pharmaceutical business models. By strategically divesting its Japanese joint venture, selectively targeting high-potential generic markets, and developing promising drug candidates like Anti-TL1A, the company has demonstrated an extraordinary ability to reimagine its core strengths. The financial metrics tell a compelling story: a 66% market capitalization increase, double-digit revenue growth, and a strategic pipeline that promises future innovation in critical therapeutic areas such as neurology and digestive system treatments. Beyond financial metrics, Teva represents a broader narrative of corporate transformation that extends beyond balance sheets. Its commitment to patient access programs, such as the recent inhaler donation initiative with Direct Relief, reveals a deeper organizational philosophy that intertwines strategic growth with social responsibility. This approach challenges the traditional perception of pharmaceutical companies as purely profit-driven entities, positioning Teva as a forward-thinking organization that understands its broader role in global healthcare ecosystems. The company's journey poses a provocative question to business leaders and investors: Can strategic vision, relentless innovation, and a commitment to patient care truly redefine a corporation's trajectory? Teva's emerging story suggests that the answer is a resounding yes—a testament to the power of adaptive strategy, visionary leadership, and an unwavering commitment to pushing the boundaries of what's possible in the pharmaceutical landscape.
NYSE:TEVALong
by signalmastermind
In the Genes for GH’s Path.Guardant Health is building strong bullish momentum, with a gap forming around the $21.50 level. A breakout above the $26.37 resistance would signal further upward movement, targeting the $37.05 weekly resistance. With an appealing 3.6 risk-to-reward ratio, this trade offers an attractive short-term opportunity, while a stop-loss at $19.19 ensures effective risk management. In the longer term, Guardant Health’s bullish outlook could extend to $41.06, supported by its advancements in precision oncology and liquid biopsy technology. With growing adoption of early cancer detection and genomic testing, Guardant Health is positioned to capture increased market share as demand for cutting-edge diagnostics rises. For those with a longer-term view, holding with a $19.19 stop-loss provides an opportunity to capture potential upside while managing downside risk. This combination of technical momentum and Guardant Health’s strong positioning in the healthcare innovation space supports a bullish push toward $37.05, with a longer-term target of $41.06.
NASDAQ:GHLong
by The_Trading_Mechanic
1
Is Pfizer's Golden Goose About to Lay a Different Egg?Pfizer, the pharmaceutical giant that became a household name during the pandemic, now faces a pivotal moment. Activist investor Starboard Value has taken a $1 billion stake, signaling potential changes on the horizon. But what does this mean for Pfizer's future? The company that swiftly developed a COVID-19 vaccine now grapples with declining sales and a tumbling stock price. Starboard's involvement brings both challenge and opportunity. Will this be the catalyst for Pfizer's renaissance or a sign of deeper troubles ahead? Former Pfizer executives have been approached to assist in the turnaround effort. Their potential involvement adds an intriguing layer to this unfolding story. Could their experience and insight be the key to unlocking Pfizer's next chapter of success and innovation? As the pharmaceutical landscape evolves post-pandemic, Pfizer's response to this pressure could set industry trends. Cost-cutting, strategic refocusing and potential leadership changes loom large. How will these moves impact drug development, patient care, and the broader healthcare ecosystem? For investors, patients, and industry watchers, Pfizer's next moves are crucial. Will the company emerge stronger, leaner, and more innovative? Or will it struggle to find its footing in a rapidly changing market? The answers to these questions could reshape the future of global healthcare.
NYSE:PFELong
by signalmastermind
2
MAXHEALTH - It is time for 1000?As always, the chart is easy to read and understand. Here are a couple of highlights for this case study: Observed a strong breakout with a long candle, currently in a retest phase. Recent price action shows a clear buyer bias. Key support levels are holding at 892 and 864. The 21-weekly EMA provides additional support. Volume spiked significantly in the last two weeks. The healthcare sector is trending upward. The first major resistance level to watch is around the 1000 mark. Disclaimer: This analysis is for educational purposes only and should not be considered as financial advice or a recommendation to buy, sell, or hold any securities. The information provided is based on historical data and market observations and does not guarantee future performance. Please conduct your own research or consult with a financial advisor before making any investment decisions. Trading in the stock market involves risk, and past performance is not indicative of future results.
NSE:MAXHEALTH
by TheChartereds
Concerned about aging? Start investing in Addus now!The aging U.S. population is set to double by 2050, increasing the need for caregivers. Addus HomeCare Corporation, based in Frisco, Texas, provides essential personal care, hospice, and home health services. With a market cap of $2.35 billion, Addus reported $1.115 billion in revenue in June 2024, with a 27% profit increase. The company is debt-free and has major shareholders like Blackrock and The Vanguard Group. EPS is forecasted to grow significantly by December 2025. With a growing need for home healthcare services, the company is well-positioned to expand its customer base and market presence. Company Overview Addus HomeCare Corporation and its subsidiaries offer personal care services for the elderly, disabled, and those at risk of hospitalization in the U.S. It operates in three areas: Personal Care, Hospice, and Home Health. The Personal Care segment helps with daily activities like bathing, grooming, and meal preparation. The Hospice segment provides care and support for terminally ill patients and their families. The Home Health segment delivers skilled nursing and therapy services for those recovering from illness or hospitalization. Its clients include government agencies, managed care organizations, insurers, and private individuals. Founded in 1979, Addus is based in Frisco, Texas. Investment Advice by Naranj Capital Buy Addus Homecare Corporation NASDAQ:ADUS ● Buy Range- 120 - 125 ● Target- 150 - 160 ● Potential Return- 25-30% ● Duration- 10 -12 Months Market Capitalization - $ 2.35B Sector - Healthcare (Nursing) Technical Analysis ● The monthly chart indicates a clear upward trend in prices. ● Earlier, the stock peaked near the 129 (128.8 to be precise) level before experiencing a correction, which was subsequently followed by an elongated consolidation period from November 2020 to July 2024. ● Recently, the stock has successfully made a multi-year breakout of the previous resistance zone and has maintained its position above this breakout level. ● We expect this momentum to persist, leading to further price increases in the days ahead. Entry, Exit & Stop-loss ● Entry with Capital allocation strategy (1) consider adding 50% of your desired quantity at the current market price (132 - 133). (2) The second buying opportunity will be in the 120 - 122 range, where you can also add rest 50% of your quantity. ● Target Chart analysis indicates a promising upside potential of 25-30% for this stock from the best buying level, with a target around the 155 to 160. There is also a strong likelihood that the stock could exceed this target. ● Stoploss It is crucial to implement a strict stop-loss below the 115 level, as we anticipate that the stock may encounter challenges if it drops to this point. Revenue Breakdown The company generates its revenue through three primary segments. (1) The personal care sector represents around 74.2% of the overall revenue, totaling $827 million out of $1.11 billion. (2) Meanwhile, hospice services contribute nearly 19.7%, amounting to $219.8 million of the total revenue. (3) The home health segment accounts for approximately 6.1%, which translates to $67.8 million of the overall revenue. Sales & Profit Analysis ● A noticeable rise in revenue has been observed. For the June quarter, revenue reached $1.115 billion, marking an 11.6% increase from $999 million in June 2023 (YoY) and a 2.5% rise from $1.08 billion in March 2024 (QoQ). ● Additionally, profits surged by 27% in the latest quarter, climbing to $68.89 million from $53.83 million in the same quarter last year, and up 5% from $65.67 million in March 2024. ● The profit margin has also improved, increasing from 5.4% to 6.2% year-on-year. ● The basic EPS for the June 2024 quarter is reported at 4.28, marking a significant increase of 27% from 3.37 in the same quarter last year. Peer Companies (1) Privia Health Group (NASDAQ: PRVA) - $ 2.41B NASDAQ:PRVA (2) Amedisys (NASDAQ: AMED) - $ 3.21B NASDAQ:AMED (3) Astrana Health (NASDAQ: ASTH) - $ 2.33B NASDAQ:ASTH Valuation ● P/E vs Fair P/E Ratio ➖ The current PE ratio stands at 34.1x, slightly expensive to the estimated Fair PE of 28.7x. ● P/E Ratio vs Peers ➖ ADUS offers great value with a Price-To-Earnings Ratio of 34.1x, significantly lower than the peer average of 62.7x. ● P/E Ratio vs Industry P/E ➖ ADUS seems to come at a higher price, boasting a Price-To-Earnings Ratio of 34.1x, notably surpassing the US Healthcare industry average of 26.2x. Debt Analysis ➖ ADUS stands proudly as a debt-free entity, a remarkable transformation from five years ago when its debt to equity ratio stood at 12.9%. This significant shift underscores the company's commitment to financial health and stability. Top Shareholders ● Blackrock currently holds a substantial 16% stake in this stock, reflecting an impressive increase of 11.2% since the March quarter. ● Meanwhile, The Vanguard Group has also boosted its investment, raising its stake by 8.5% from the previous quarter, bringing their total holding to 7.74%. Earnings per Share Growth Forecasts Experts forecast that the earnings per share (EPS) could increase from $4.28 to $4.51 by December 2024, and further rise to $5.03 by December 2025. Conclusion With the growing need for home healthcare services, the company is well-positioned to broaden its customer base and enhance its market presence.
NASDAQ:ADUSLong
by NaranjCapital
1
Eli Lilly's Zepbound: A Game-Changer for Obesity Treatment?In a groundbreaking move that could redefine the landscape of obesity treatment, Eli Lilly has slashed the price of its weight loss drug, Zepbound, by half. But is this simply a strategic business decision, or is it a beacon of hope for millions struggling with obesity? Join us as we delve into the implications of this bold move and explore the potential impact on the future of weight management. Imagine a world where obesity is no longer a daunting, insurmountable challenge. A world where effective, affordable treatments are accessible to all who need them. Eli Lilly's recent announcement of a significant price reduction for Zepbound brings us closer to that reality. By making this groundbreaking decision, Eli Lilly has not only demonstrated its commitment to patient access but has also sent a powerful message to the broader healthcare industry. This move has the potential to disrupt the status quo, challenging the outdated policies and practices that have hindered progress in obesity treatment. As we explore the implications of Eli Lilly's decision, we must consider the broader context of the obesity epidemic. For decades, obesity has been stigmatized and overlooked as a serious medical condition. Many individuals struggling with weight loss have faced limited treatment options and significant financial burdens. Eli Lilly's move to lower the price of Zepbound could be a game-changer in this regard. By making the drug more affordable, the company is empowering patients to take control of their health and pursue a healthier lifestyle. This could lead to a significant increase in the number of people seeking treatment for obesity, ultimately improving public health outcomes. However, it is important to note that this is just one step in a larger journey. While Eli Lilly's decision is undoubtedly a positive development, more needs to be done to address the systemic issues that contribute to the obesity epidemic. Policymakers, healthcare providers, and communities must work together to create a supportive environment that promotes healthy eating, physical activity, and access to affordable, effective treatments. In conclusion, Eli Lilly's announcement of a price reduction for Zepbound represents a significant milestone in the fight against obesity. By making this drug more accessible, the company is not only helping individuals achieve their weight loss goals but also challenging the broader healthcare system to prioritize obesity treatment.
NYSE:LLYLong
by signalmastermind
Centene Corp | CNC | Long at $65As a managed health care company, Centene Corp NYSE:CNC doesn't get much attention. However, it is an undervalued growth stock. It's been a workhorse historically for slow and steady financial returns with a 3%+ dividend. The biggest dips along my selected moving average have been into the blue lines - which it recently tested. While the stock may close the gap near $62 is the near future, it's a personal buy at $65. Target 1 = $78.00 Target 2 = $95.00
NYSE:CNCLong
by WorthlessViews
1
Swing Trading Setups: TWSTThis is a stock that went on my students' watchlists this week for potential swing trading. NASDAQ:TWST is coming out of a long-term down-trending correction and has completed the bottom. Accumulation ended and a HFT gap and run up followed on May 3rd. The stock retested the sideways trend highs which are now support for the current price. Pro traders are swing trading in these patterns. There are fewer wicks and tails and the stock has a very high Percentage of Shares Held by Institutions.
NASDAQ:TWST
by MarthaStokesCMT-TechniTrader
HIMS a gender focused health care company LONGHIMS had an excellent earnings report for a small cap company; it is consumer driven quality focused and helps the customer feel good about him/her- self. It does not have any gender orientation agenda nor any obvious political inclinations. On the 120 minute chart, it started a moving averge convergence about a week before earnings. The Greeny TTM squeeze indicator did its thing as the post-earnings action began. I see this stock as a good long to hold into the next earnings and perhaps through it. HIMS is now at its all time high. There is no chart horizontal resistance overhead and traders will note that. I see the bullish momentum continuing perhaps with some healthy ( no pun intended) corrections while underway. Healthcare is considered to be a hot sector for 2024 this small cap seems to be warmed up.
NYSE:HIMSLong
by AwesomeAvani
UNITED HEALTH Time to buy again?Last time we looked into United Health (UNH) we gave a strong buy signal (October 03 2023, see chart below), which turned out to be very successful: After getting rejected on Resistance 3, the stock started to decline structurally within a Channel Down. It is a pattern similar to the Channel Down of November 2022 - March 2023, which was again formed after UNH got rejected within the 2-year Resistance Zone, like it happened this time. There is a high symmetry these past 2 years within the Resistance and Support Zones, so we expect the price to act accordingly. As a result, having already formed a 1D Death Cross, we expect the price to make one last Low towards the Support Zone (as long as the 1D MA50 holds as Resistance) and then rebound, which is what took place on March 10 2023, above the 0.618 Fibonacci retracement level. As a result, we will time our buy accordingly and target $517.00 (Fib 0.618). An additional buy signal would be if the 1W RSI makes a Double Bottom, similar again to March 10 2023. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:UNH
by TradingShot
ELI LILLY Going to $1050 but after a 1D MA50 correction.Eli Lilly (LLY) has basically turned sideways since the February 16 High. The dominant pattern is a Channel Up since the March 07 2023 Low and can be divided into 3 Bullish Waves that delivered rallies between +45% and +52%. Every time the price hit the 1D MA50 (blue trend-line), it was a buy opportunity. The 1D RSI in particular has a Buy Zone, which coincided with all those dip buy opportunities within the Channel Up. As a result, since the stock has already completed a +45% rise from the October 31 2023 Low, we do expect a pull-back to start soon towards the RSI Buy Zone, but only after it rises a little again and forms a Lower High on the RSI, which would be consistent with the previous top formation on the Channel Up. In any case, at any point the RSI hits its Buy Zone, we will position ourselves with a long and aim for a new +45% rise. Rough target from the current projection is $1050. Notice how efficiently the peak and bottom formations are caught by the Sine Waves. A very symmetric pattern for the long-term indeed. ------------------------------------------------------------------------------- ** Please LIKE 👍, FOLLOW ✅, SHARE 🙌 and COMMENT ✍ if you enjoy this idea! Also share your ideas and charts in the comments section below! This is best way to keep it relevant, support us, keep the content here free and allow the idea to reach as many people as possible. ** ------------------------------------------------------------------------------- 💸💸💸💸💸💸 👇 👇 👇 👇 👇 👇
NYSE:LLY
by TradingShot
Dr Lal Pathlabs Ltd can it double in one year?Dr Lal Pathlabs one of the largest players of healthcare industry in India has a beaten down stock price currently. It is approximately 53.29% down from it's lifetime high. There is not a single reason for such stock price. The company is posting good results and is consistently showing profits. But the stock is highly undervalued. It is a good time to buy it as the current levels make it a precious deal to make. Hope you like my analysis. Please do your own study before investing. Do like and follow and share among your family and friends. Thank you.
NSE:LALPATHLABLong
by ronak16125
UNH, the dominate health insurance market leader LONGAs shown on the 4H chart, UNH based on a long-term VWAP band setup, it as fiar value for the first time since September. This dip is significant as price fell from a head and shoulders pattern of three months duration. The candles in the past couple of days show the reversal at the mean VWAP support. I have retrieved 60% out of a near term expiration call option. Some may say this is simply a death cross on a pair of moving averages with a bit of correction on the overall downtrend. I understand that point of view. Notwithstanding that perspective, healthcare is expected to be an outperforming sector in 2024. UNH is on sale. As a healthcare provider, it has paid me large sums in the historical past. I will take trades as described in the text box on the chart. I believe buying out of the money and at a discount will be a good strategy for this megacap moving forward.
CAPITALCOM:UNHLong
by AwesomeAvani
The Healthcare Sector Index $XLV - Worth Watching SPDR Select Sector Fund – Healthcare Index AMEX:XLV The chart speaks for itself, we have our breakout levels and our break down levels. We enter on a breakout and set a stop 5% under that support and we exit and or short if we fall under the two underside support levels. Below I outline some reasons why the healthcare sector is worth paying attention too. The healthcare industry is worth $808 billion in the United States as of 2021. 65% of the industry’s revenue comes from patient care. The global healthcare industry is worth $12 trillion. In the U.S National health expenditures are projected to grow 5.4 percent, on average, over the course of 2023–31 and to account for roughly 20 percent of the economy by the end of that period. The insured share of the population is anticipated to exceed 92 percent through 2023 (figures pending), in part as a result of record-high Medicaid enrolment, and then decline toward 90 percent as coverage requirements related to the COVID-19 public health emergency expire. The growth of the health-care sector is evident in employment data as well. In 1990, about 8 million Americans worked in health care; that figure has since doubled to 16 million. That’s the largest single employment segment in our economy. In addition to the above, the west in general is an aging populace that is living longer. We will need these services more than we need staples during a recession. I believe this index can help us gauge the healthcare sector and what direction it will go next. We can watch the levels outlines and make a play if we wish. We have a hard upper boundary and lower boundary on a parallel channel on the chart. You know what to do when we breach any of these levels. Outlined on the chart XLV fund provides exposure to companies in pharmaceuticals, health care equipment and supplies, health care providers and services, biotechnology, life sciences tools and services, and health care technology industries. XLV is the oldest in the segment, as such it is used widely for strategic or tactical positions. Since XLV is both cap weighted and fishes only from the S&P 500, it tilts heavily toward mega-caps. For focused exposure to leading health care names, XLV is tough to beat. Top Five Holdings UnitedHealth Group Inc NYSE:UNH 9.63% Eli Lilly and Co NYSE:LLY 9.19% Johnson & Johnson NYSE:JNJ 7.46% Merck & Co NYSE:MRK 5.46% AbbVie Inc 5.41% Stay Healthy and Nimble Folks PUKA
AMEX:XLV
by PukaCharts
Analysis of CVS Stock Trends: A Parabolic Turn on the HorizonFashionable Analysis of CVS Stock Trends: A Parabolic Turn on the Horizon Introduction: In the realm of financial fashion, CVS stock is set to make a stylish entrance with a parabolic turn, showcasing a strong formation on the 4D timeframe. This trend is marked by the elegant falling wedge pattern and the chic double bottom overlapping patterns, following a dose of impactful news related to drug patents. Technical Analysis - CVS Stock: The 4D timeframe reveals the graceful formation of a falling wedge pattern, signifying a poised parabolic turn in CVS stock. This pattern, complemented by double bottom overlapping formations, is a testament to the stock's resilience, especially against the backdrop of recent drug patent news highlighted on CNBC ( www.cnbc.com ). Price Targets and Corrections: The first take profit target stands confidently at $76.78, offering investors a lucrative moment to capitalize on the impending parabolic turn. Following this peak, a correction to approximately $71.07 is expected, providing a brief pause for market adjustments. Strategic Entry and Second Take Profit Target: Wise investors can strategically enter the market around $71.07, anticipating a second take profit target at a stylish $82.44. This forecasted move aligns with the rhythm of the stock's recent patterns, emphasizing the importance of timing in the world of financial fashion. Historical Elegance: Tracing CVS stock's journey since April 2019, a period marking the middle of the pandemic, unveils a remarkable rally. The stock gracefully formed a strong falling wedge pattern on the 4Day timeframe, echoing a sense of resilience and adaptability. The rally continued, reaching its peak around February 01, 2022, before gracefully correcting until October 25, 2023. Future Projections: As the music of the market plays on, further continuation of this trend is expected. The forecasted trajectory anticipates a new level of elegance for CVS stock by the end of 2024, reaching a poised $106.97. This future projection exudes confidence and sets the stage for CVS to make a bold statement in the financial fashion world. In the intricate dance of stocks and patterns, CVS is poised to captivate investors with its upcoming parabolic turn and a tale of resilience, gracefully crafted on the canvas of market trends.
NYSE:CVSLong
by wikitrades
Is Sanofi Undervalue by 22% ?I wanted to share an analysis I've conducted on Sanofi over the past five years using both comparable methods and a 2-Stage DCF approach. According to my findings, the market value appears to be at least 22% undervalued in comparison with its fair value. Moreover, considering the post-COVID effects on pharmaceutical companies, I believe Sanofi presents a compelling opportunity to purchase its stock with potentially lower risk. I would be glad to share my detailed analysis for any one interested in more in debt explorations Disclaimer: This information is based on my personal analysis and is not to be considered financial advice. I am expressing my own views and opinions on the current market conditions and Sanofi's stock. Always conduct your own research and consider seeking advice from a qualified financial professional before making any investment decisions.
EURONEXT:SANLong
by arya1992
Pfizer (PFE) -> It Is Now Or NeverMy name is Philip, I am a German swing-trader with 4+ years of trading experience and I only trade stocks , crypto , options and indices 🖥️ I only focus on the higher timeframes because this allows me to massively capitalize on the major market swings and cycles without getting caught up in the short term noise. This is how you build real long term wealth! In today's anaylsis I want to take a look at the bigger picture on Pfizer. At the moment Pfizer stock is once again retesting major sructure at the psychological $33 level which already acted as pretty strong support in the past. Considering that the next support level below current price is at $27, Pfizer is now trading at a pretty decisive potential turning point and has not yet broken structure towards the downside. - - - - - - - - - - - - - - - - - - - - I know that this is a quite simple trading approach but over the past 4 years I've realized that simplicity and consistency are much more important than any trading strategy. Keep the long term vision🫡
NYSE:PFELong
by basictradingtv
20